NSCLC Autoantibody Panel Using Biotinylated Antigen Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for Non-Small Cell Lung Cancer (NSCLC) have low sensitivity and specificity, poor prognostic/predictive value, and are not crucial for clinical decision-making, with many overlapping with other diseases, limiting their clinical use.
Innovation Solution
A panel of autoantibody biomarkers, including XAGE1D, LRRFIP2, and GAGE2C, is used for diagnosing NSCLC, utilizing biotinylated antigens bound to streptavidin-coated substrates, with exosomal samples, and fluorescently-tagged secondary antibodies to determine autoantibody levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein biomarkers are used for NSCLC diagnosis, then detection can be performed, but sensitivity and specificity are low and overlap with other diseases
Solution Approach 1:
The invention segments the diagnostic approach by using a panel of multiple autoantibody biomarkers (including XAGE1D, LRRFIP2, and GAGE2C) instead of relying on a single protein biomarker. This segmentation allows for more specific detection patterns that are unique to NSCLC, reducing overlap with other diseases while maintaining high sensitivity.
Solution Approach 2:
The invention changes the fundamental parameter being measured from protein levels to autoantibody responses against specific antigens. This parameter change enables detection of the immune system's response to NSCLC-specific antigens, providing higher diagnostic accuracy and specificity compared to direct protein measurement.
2Reliability
If a panel of multiple biomarkers is used, then diagnostic accuracy improves, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The invention employs a universal detection platform that can simultaneously measure multiple autoantibody biomarkers in a single assay. The streptavidin-coated substrate with multiple antigens allows one test to perform the function of multiple individual tests, maintaining high diagnostic accuracy while simplifying the overall testing process.
Solution Approach 2:
The invention merges multiple biomarker detection capabilities into a single integrated assay platform. By combining multiple antigens (XAGE1D, LRRFIP2, GAGE2C, and others) on one streptavidin substrate, the system achieves high diagnostic accuracy without requiring separate tests for each biomarker, thus reducing practical complexity.
3Measurement precision
If biotinylated antigens are used to ensure correct folding, then detection accuracy improves, but manufacturing complexity increases
Solution Approach 1:
The invention uses biotin as an intermediary molecule that facilitates correct antigen folding and provides a standardized binding interface. The biotin-streptavidin interaction serves as a reliable mediator that ensures proper antigen conformation while simplifying the manufacturing process through a well-established, high-affinity binding system.
Solution Approach 2:
The invention changes the manufacturing approach by using chemical biotinylation of antigens rather than relying on complex folding protocols. This parameter change transforms the manufacturing challenge into a straightforward chemical modification step, ensuring correct folding and functional activity while simplifying production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides improved sensitivity and specificity for NSCLC diagnosis, enabling early detection, patient stratification, and treatment monitoring, with a success rate exceeding 98% and high-throughput capability.
Implementation Method 1
biotinylated antigens bound to streptavidin-coated substrates
Implementation Method 2
fluorescently-tagged secondary antibodies to determine autoantibody levels
Data Source
AI summary
A method for diagnosing Non-Small Cell Lung Cancer (NSCLC) from a sample extracted from a subject by testing the sample for the presence of biomarkers, the biomarkers being autoantibodies against XAGE1D, LRRFIP2 and GAGE2C. Also claimed are a method of manufacturing a kit, and compositions comprising a panel of said antigens or exosomal autoantibodies.